Research programme: anticancer therapeutics - Molecular Templates/Takeda Oncology
Latest Information Update: 09 May 2025
At a glance
- Originator Molecular Templates; Takeda Oncology
- Class Antineoplastics; Peptides
- Mechanism of Action CD38 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 May 2025 Discontinued for Cancer in USA (Parenteral)
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from in-vitro and preclinical studies presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)